You searched for non small cell lung cancer

Drugs in the Pipeline

Trial Evaluating Tiragolumab Combo in PD-L1 High NSCLC Misses PFS Endpoint

May 11, 2022

The phase 3 study compared tiragolumab plus atezolizumab with placebo plus atezolizumab in adults with PD-L1 high locally advanced, unresectable or metastatic NSCLC.

Drugs in the Pipeline

Durvalumab Plus Chemo Granted Priority Review for Biliary Tract Cancer

May 4, 2022

The sBLA was supported by data from the phase 3 TOPAZ-1 trial.

Drugs in the Pipeline

Trastuzumab Deruxtecan Gets Priority Review for Previously Treated HER2-Mutant Metastatic NSCLC

April 19, 2022

The sBLA is supported by data from the phase 2 DESTINY-Lung01 trial, along with a phase 1 trial published in Cancer Discovery.

News

Bevacizumab Biosimilar Alymsys Gets FDA Approval

April 14, 2022

The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.

Drugs in the Pipeline

Trial Evaluating Tiragolumab Combo for Extensive-Stage SCLC Misses Endpoint

March 30, 2022

Tiragolumab is a monoclonal antibody that works by binding to TIGIT, a protein receptor on immune cells, and suppresses the immune response to cancer.

Drugs in the Pipeline

FDA Rejects Sintilimab Combo for First-Line Treatment of Nonsquamous NSCLC

March 25, 2022

Sintilimab is an investigational programmed death receptor-1 (PD-1) inhibitor.

News

Opdivo Plus Chemotherapy Approved for Neoadjuvant Treatment of Resectable NSCLC

March 7, 2022

The approval was based on data from the CHECKMATE-816 trial.

Drugs in the Pipeline

Adagrasib Under Review for Previously Treated KRAS G12C-Mutated NSCLC

February 16, 2022

The application is supported by data from the registration-enabling cohort of the phase 2 KRYSTAL-1 study evaluating adagrasib in adults with NSCLC harboring the KRASG12C mutation following prior systemic therapy.

News

FDA Panel Rejects Lilly Cancer Drug Tested Only in China

February 14, 2022

Drug was to be used alongside chemotherapy for patients with metastatic non-small cell lung cancer

Drugs in the Pipeline

Poziotinib Under Review for Previously Treated HER2 Exon 20 Insertion Mutation Positive NSCLC

February 11, 2022

A PDUFA target date of November 24, 2022 has been set for the application.

Active Filters

Your search for non small cell lung cancer returned 432 results

Sort Results:

Trial Evaluating Tiragolumab Combo in PD-L1 High NSCLC Misses PFS Endpoint

Durvalumab Plus Chemo Granted Priority Review for Biliary Tract Cancer

Trastuzumab Deruxtecan Gets Priority Review for Previously Treated HER2-Mutant Metastatic NSCLC

Bevacizumab Biosimilar Alymsys Gets FDA Approval

Trial Evaluating Tiragolumab Combo for Extensive-Stage SCLC Misses Endpoint

FDA Rejects Sintilimab Combo for First-Line Treatment of Nonsquamous NSCLC

Opdivo Plus Chemotherapy Approved for Neoadjuvant Treatment of Resectable NSCLC

Adagrasib Under Review for Previously Treated KRAS G12C-Mutated NSCLC

FDA Panel Rejects Lilly Cancer Drug Tested Only in China

Poziotinib Under Review for Previously Treated HER2 Exon 20 Insertion Mutation Positive NSCLC